Learn more about our approach to sustainability and achievements by exploring our news, case studies, global policies, reports and multimedia content.
Policies and position statements
This document outlines our approach to making our medicines available and affordable, and how we work together with healthcare systems to support sustainable access to healthcare.
Our Global ABAC Standard supports our commitment to operate ethically, specifically explaining how to be people of integrity in all of our dealings with third parties of any kind.
This policy defines the principles, behaviours and ethical standards behind our global R&D efforts. It covers topics such as: clinical trials, patient safety, privacy of information, genomic information, GMOs, animals in research, Nagoya protocol, etc.
These Global Standards set out our expectations for behaviour to ensure everyone feels respected, supported and safe at work from any form of bullying and harassment, be it mental, physical or sexual.
Our Code of Ethics is the foundation for our sustainability strategy. It defines our values at work and guides everything we do, ensuring that we deliver life-changing medicines in a responsible way.
This document details our approach to monitoring conflict minerals that may be used to manufacture our products.
Sets out requirements for processing personal data and aligns with and, in some cases, exceeds the requirements of applicable laws and regulations. We value the personal data entrusted to us, and we are committed to collecting, using, retaining, and disclosing personal data in a fair, transparent and secure way.
We recognise that there are circumstances where patients with serious or life-threatening diseases have exhausted all available therapeutic options and may not be eligible to enrol in one of our clinical trials. In such circumstances individual patients may be eligible for early access to an AstraZeneca investigational medicinal product.
This document provides the minimum standards for the identification and assessment of ergonomic hazards and other human factors. Ergometry refers designing workplaces for employees' physiological and psychological needs.
This handbook summarises what AstraZeneca believes is required to do the right thing and what we expect of all Third Parties that work with us, for us, or on our behalf. These expectations are part of our fundamental commitment to work only with others who embrace ethical standards consistent with ours.
In our Gender Pay Gap Reports, we provide gender pay information for AstraZeneca in the United Kingdom and outline our plans for supporting women, as well as continuing to improve the diversity of our company globally.
When we promote our products, we provide accurate information based on scientific evidence.
This statement details how AstraZeneca respects the rights of all stakeholders - including employees, patients, suppliers, communities, and the environment. We are committed to treating everyone with dignity and respect and to ensuring that third parties we work with do the same.
This statement describes our commitment to expand access to healthcare through intellectual property (IP). AstraZeneca sees IP as a driver for innovation that will lead to the discovery of new medicines.
AstraZeneca is committed to operating with integrity and high ethical standards. This includes ensuring that our business respects human rights - a commitment reflected in our Code of Ethics, which is based on our Company Values and includes our global “Our Interactions” Policy. Specifically, we are committed to ensuring that we identify and eliminate to the fullest extent practicable modern-day slavery or human trafficking in our business.
This document intends to make our tax approach transparent by detailing our governance, risk management, compliance, tax planning, dealings with tax authorities, etc.
As a responsible healthcare company, we make it a priority to effectively manage the risks associated with pharmaceuticals in the environment (PIE).
We follow Good Publications Practice guidelines and ICMJE Recommendations in sharing objective, meaningful scientific information about our studies without compromising our intellectual property.
This guide builds on our compliance expectations to describe our vision for supply chain sustainability. It also provides a common way to assess and reward performance by our sourcing teams.
This document describes the process that needs to be followed for any vendor/contractor laptops, removable storage devices and any new equipment/servers from outside of AstraZeneca, before they connect their devices to the AstraZeneca Segregated Network.
Our Water Stewardship position paper sets out our approach to minimising our impact on water and making a positive contribution to water stewardship in the river basins where we operate.
This document outlines workplace noise and vibration hazards, with the objective of protecting people from health effects associated with poor management of these issues.
Annual sustainability reporting
Our Annual sustainability reporting section includes supplementary and complementary information to our annual Sustainability report.
Find more in-depth information here on our Access to healthcare strategy, employee well-being, supply chain, greenhouse gas emissions, etc.
This is our third sustainability report, and it describes our progress and challenges in 2017. The content of this report is based on those sustainability issues deemed material through formal stakeholder engagement and analysis.
This summary is meant to provide employees with the essential information on our sustainability strategy and initiatives in 2017.
Here you can see metrics for each of AstraZeneca's sustainability priorities - Access to Healthcare, Environmental Protection, Ethics & Transparency and Foundations - from 2015, 2016, and 2017.
Bureau Veritas independently verified sustainability information of the 2017 Annual Report.
This graphic shows the impacts HHA has had on people’s lives in numbers, in terms of trained healthcare workers, healthcare facilities activated, etc.
Bureau Veritas independently verified the target statuses of the 2017 Sustainability Report.
This graphic shows issues that are material for AstraZenenca and its diverse stakeholders. Each issue is categorized into one of our 4 priority areas - Access to Healthcare, Environmental Protection, Ethics & Transparency, and Foundations.
This graphic shows how AstraZeneca is responding to non-communicable diseases (NCDs) across various countries.
This graphic shows how each region across the world is participating in employee Global Health & Well-Being Programmes. These programmes include four essential health activities - Physical activity, Healthy drinking & eating, Stress/pressure management, and Tobacco cessation.
This graphic gives details on hypertension (high blood pressure), its effects on patients and the economy, and its prevalence in Africa.
This graphic explains how we are working to reduce GHG emissions, across the three main parts of our value chain - Upstream, Operations, and Downstream.
This graphic explains how our pre-clinical animal studies tests are run, through a process called the 3Rs (Replacement, Refinement, and Reduction).
This graphic details our efforts to drive and foster a responsible supply chain. We do this through quality audits, environmental assessments, and third-party risk management assessments.
This document outlines the history of HHA, its milestones in providing access to healthcare, and importance in a region burdened by hypertension (high blood pressure).
Code of Ethics
Our Code of Ethics defines our values at work and guides everything we do, ensuring that we deliver life-changing medicines in a responsible way.
Partnership with Royal Academy of Engineering to bolster support for African health tech entrepreneurs
Veeva ID: Z4-39263
Date of preparation: December 2021